[go: up one dir, main page]

AU2012371260A8 - Predicitive biomarker for cancer treatment with ADCC enhanced antibodies - Google Patents

Predicitive biomarker for cancer treatment with ADCC enhanced antibodies

Info

Publication number
AU2012371260A8
AU2012371260A8 AU2012371260A AU2012371260A AU2012371260A8 AU 2012371260 A8 AU2012371260 A8 AU 2012371260A8 AU 2012371260 A AU2012371260 A AU 2012371260A AU 2012371260 A AU2012371260 A AU 2012371260A AU 2012371260 A8 AU2012371260 A8 AU 2012371260A8
Authority
AU
Australia
Prior art keywords
predicitive
biomarker
cancer treatment
enhanced antibodies
adcc enhanced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012371260A
Other versions
AU2012371260A1 (en
Inventor
Christian Gerdes
Claude GIMMI
Simon HOLLINGSWORTH
Luigi MANENTI
Ruediger Rueger
Pablo Umana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Glycart AG
Original Assignee
Roche Glycart AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart AG filed Critical Roche Glycart AG
Publication of AU2012371260A1 publication Critical patent/AU2012371260A1/en
Publication of AU2012371260A8 publication Critical patent/AU2012371260A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
AU2012371260A 2012-03-02 2012-03-02 Predicitive biomarker for cancer treatment with ADCC enhanced antibodies Abandoned AU2012371260A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2012/053600 WO2013127465A1 (en) 2012-03-02 2012-03-02 Predicitive biomarker for cancer treatment with adcc enhanced antibodies

Publications (2)

Publication Number Publication Date
AU2012371260A1 AU2012371260A1 (en) 2014-07-10
AU2012371260A8 true AU2012371260A8 (en) 2014-09-18

Family

ID=45814493

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012371260A Abandoned AU2012371260A1 (en) 2012-03-02 2012-03-02 Predicitive biomarker for cancer treatment with ADCC enhanced antibodies

Country Status (8)

Country Link
JP (1) JP2015511702A (en)
KR (1) KR20140130455A (en)
AU (1) AU2012371260A1 (en)
BR (1) BR112014018374A8 (en)
CA (1) CA2860369A1 (en)
MX (1) MX2014010379A (en)
RU (1) RU2014138586A (en)
WO (1) WO2013127465A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
TWI693073B (en) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients
WO2014114595A1 (en) 2013-01-23 2014-07-31 Roche Glycart Ag Predictive biomarker for cancer treatment with adcc-enhanced antibodies
KR102409014B1 (en) * 2014-05-08 2022-06-14 추가이 세이야쿠 가부시키가이샤 Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
WO2017002934A1 (en) * 2015-07-01 2017-01-05 中外製薬株式会社 Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (en) 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
ATE419355T1 (en) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
JP4334141B2 (en) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity
CA2455365C (en) 2001-08-03 2014-07-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
PL224786B1 (en) 2003-01-22 2017-01-31 Glycart Biotechnology Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
EP2402374A1 (en) 2005-02-07 2012-01-04 GlycArt Biotechnology AG Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
AR062223A1 (en) 2006-08-09 2008-10-22 Glycart Biotechnology Ag MOLECULES OF ADHESION TO THE ANTIGEN THAT ADHER TO EGFR, VECTORS THAT CODE THEM, AND THEIR USES OF THESE
ATE501436T1 (en) * 2006-09-13 2011-03-15 Glycode METHOD FOR STUDYING THE RESPONSE TO TREATMENT WITH A MONOCLONAL ANTIBODY
AR075982A1 (en) * 2009-03-31 2011-05-11 Roche Glycart Ag COMBINATION THERAPY OF A AFUCOSILATED ANTIBODY AND ONE OR MORE OF THE SELECTED CYTOKINS OF GM-CSF HUMAN, M-CSF HUMAN AND / OR IL-3 HUMAN AND COMPOSITION
EP2513336B1 (en) * 2009-12-16 2016-03-02 Hitachi Chemical Co., Ltd. Method for characterizing host immune function by ex vivo induction of offensive and defensive immune markers

Also Published As

Publication number Publication date
JP2015511702A (en) 2015-04-20
BR112014018374A2 (en) 2017-06-20
WO2013127465A1 (en) 2013-09-06
CA2860369A1 (en) 2013-09-06
RU2014138586A (en) 2016-04-20
KR20140130455A (en) 2014-11-10
MX2014010379A (en) 2015-05-15
AU2012371260A1 (en) 2014-07-10
BR112014018374A8 (en) 2017-07-11

Similar Documents

Publication Publication Date Title
MX2015012122A (en) Antibody drug conjugates and corresponding antibodies.
TN2015000396A1 (en) Antibody drug conjugates
AU2011338480A8 (en) Humanized antibodies to LIV-1 and use of same to treat cancer
MX2016002826A (en) Anti-b7-h1 antibodies for treating tumors.
NZ702748A (en) Cd33 antibodies and use of same to treat cancer
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2014009751A (en) Antibodies to integrin avvb6 and use of same to treat cancer.
GEP20217331B (en) Anti-tigit antibodies
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
IN2014DN05885A (en)
PH12014501543A1 (en) Combination therapy for the treatment of ovarian cancer
MX2017000840A (en) Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer.
IN2014DN09717A (en)
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
MX347463B (en) Combination therapy of an afucosylated cd20 antibody with an anti-vegf antibody.
MX2014006187A (en) Compositions and methods for prostate cancer analysis.
WO2013052108A3 (en) Methods and compositions for the treatment and diagnosis of ovarian cancer
MX362497B (en) Methods for treatment of gastric cancer.
PH12014502461A1 (en) Biomarkers for iap inhibitor therapy
WO2013040358A3 (en) Assays and compositions for detection of agr2
WO2012106473A3 (en) Dosing for treatment with anti-egfl7 antibodies
IN2014CN02496A (en)

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 28 , NO 27 , PAGE(S) 3655 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME ROCHE GLYCART AG, APPLICATION NO. 2012371260, UNDER INID (71) CORRECT THE APPLICANT NAME TO ROCHE GLYCART AG

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application